David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.
The paradigm for drug development is changing in lung cancer, though new concepts and themes can be applied to all cancers. Gandara says drug development has been ineffective to date for cancer therapies as a whole.
There remains a need for new ways of thinking, new strategies, and new clinical trial designs to increase the likelihood of benefit for patients with specific genomic abnormalities.
Currently, less than 5% of cancer drugs actually make it to patients, Gandara says. This also needs to be improved.
<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology